Author Archives: Kiran Dhillon

Announcing the 2018 Rivkin Center Research Grant Awardees

infographic-header

As one of the largest private funders of ovarian cancer research, we’re excited to announce the awardees of this year’s pilot and scholar research grants. Over 170 applications poured in from around the world. Fourteen were chosen. Why is funding scientific research important? Ovarian cancer kills more than 22,000 women every year in the United […]

Highlights of Ovarian Cancer Science from ASCO

Dr. Rivkin and I attended the annual meeting of the American Society of Clinical Oncology (ASCO)—a gathering of 38,000 oncology experts from all over the world—in early June in Chicago, Illinois. In addition to oncologists, the attendees included researchers, educators, advocates, research funders, survivors and representatives from genetic testing, drug and other services companies. Our […]

New study extends benefit of Rucaparib PARP inhibitor to women with BRCA defects in tumors who do not carry inherited BRCA mutations

A study published in Lancet Oncology by Dr. Iain McNeish (2016 Rivkin Pilot Award Recipient), Dr. Elizabeth Swisher (2009 Rivkin Pilot Award Recipient), and colleagues provided key data that helped fuel the FDA’s recent approval of rucaparib for ovarian cancers with defects in the BRCA1 and BRCA2 genes in women previously treated with two or more chemotherapies.

X